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INTRODUCTION
Clostridium difficile (C. difficile) is the leading cause of healthcare-associated infections
in the United States. According to recent data from the Center of Disease Control (CDC’s)
National Healthcare Safety Network, 3644 U.S. hospitals reported 98,448 cases of hospitalonset clostridium difficile infections (CDI), with over 80% hospitals having one or more cases
(Gould & McDonald, 2009). In 2014, a national prevalence survey found that Clostridium
difficile was not only the most commonly reported pathogen, but caused 12% of health careassociated infections in the United States (Magill et al., 2014). Each year, an estimated 14,000
deaths are attributed to CDI, resulting in a mortality rate of 6.9% at 30 days after diagnosis and
16.7% at one year (E. Dubberke, 2012; Erik Dubberke et al., 2008). Consequently, it cost an
estimated $5,000 - $7,000 in healthcare expenses per case, totaling at an estimated $1 billion
to $1.6 billion dollars annually (Scott, 2009). Due to this epidemic, multiple hospitals across the
United States have implemented prevention collaboratives in an effort to decrease the rate of
CDI (Control & Prevention, 2015). As a result, the CDC indicated several of the participating
hospitals observed an overall decrease in the incidence of CDI.
C. difficile is a gram positive anaerobic bacterium that causes potentially deadly
diarrhea, which can be spread in healthcare settings (Kelly & LaMont, 2008; Paredes, Alsaker, &
Papoutsakis, 2005). Most cases of CDI occur in patients previously exposed to prolonged cycles
of antibiotics. As a patient takes antibiotics, their microflora, or “good bacteria”, which protect
against infections are decreased for several months. During this time, C. difficile in the

vegetative stage can invade the patient’s intestines, colonize, and causes infection (Kuipers &
Surawicz, 2008; Seekatz & Young, 2014). Most often C. difficile is contracted nosocomially, but
can also be transferred from person to person through the fecal-oral route (Kyne, Farrell, &
Kelly, 2001; Tabaqchali & Wilks, 1992). In most cases of antibiotic associated
pseudomembranous colitis, C. difficile is the primary cause (Bartlett, 1994). CDIs are difficult to
treat because of its ability to form endospores, which are resistant to extreme conditions
including high temperatures, ultraviolet light, antiseptics, and antibiotics. They can survive in
the environment for up to two years (Underwood et al., 2009). Due to this resistance, spores
can remain in a patient’s gastrointestinal tract for extended periods of time, causing recurrent
CDIs following eradication of vegetative C. difficile.
Most vegetative bacterial cells are killed by the acidic environment in the stomach.
However, C. difficile spores can survive this environment, allowing passage to the intestines. An
increased incidence of CDI in some studies has been correlated with the use of proton pump
inhibitors, particularly in combination with antibiotics (Dial, Delaney, Barkun, & Suissa, 2005;
Dial, Delaney, Schneider, & Suissa, 2006). There is evidence that proton pump inhibitors can
affect the microbiota of the gastrointestinal tract both by lowering the environmental pH and
by a direct effect of the drug on bacteria (Altman et al., 2008) (Vesper et al., 2009).
In vitro studies suggest that the germination and outgrowth of the C. difficile endospore
are dependent on the exposure of specific bile acids, primarily taurocholate in combination
with glycine (Heeg, Burns, Cartman, & Minton, 2012; Sorg & Sonenshein, 2010). The
dependency of C. difficile spore germination with bile acids is a direct result of their ability to

utilize sugars and undergo the metabolic process of amino acid fermentation to create ATP as a
source of energy (Jackson, Calos, Myers, & Self, 2006). A polysaccharide capsule discourages
phagocytosis of the C. difficile bacterium, while flagella facilitate its movement. As C. difficile
colonize, the bacterium adheres to the colonic epithelium. By prioritizing growth over toxin
production, C. difficile can exponentially grow and colonize dramatically before producing
detectable toxins (Dupuy & Sonenshein, 1998). This can make identifying patients with a
progressing CDI quite difficult when using toxin based screening.
As C. difficile growth slows, production of its two virulence factors, enterotoxin (toxin A)
and cytotoxin (toxin B), as well hydrolytic enzymes begins. If untreated, the production of
toxins A and B result in increased vascular permeability, neutrophil and monocyte recruitment,
production of tumor necrosis factor-alpha and pro-inflammatory interleukins, opening of
epithelial cell junctions, and eventually epithelial cell apoptosis. The production of hydrolytic
enzymes leads to connective tissue degradation, pseudomembrane formation, watery diarrhea,
and eventually colitis (Weston, 2008).
The most common treatments for CDI are vancomycin and metronidazole, which
eradicate C. difficile’s cell wall inducing cell death (Kuipers & Surawicz, 2008; Zheng et al.,
2007). However, these treatments are only viable for vegetative C. difficile, having little to no
effect on C. Difficile spores. When standard treatment has failed, one strategy that has been
shown to be effective in eradicating C. difficile in patients with recurrent CDIs is intestinal
microbiota transplantation (IMT), also known as the fecal transplant. IMT is an alternative
therapy for CDI patients that involve infusing intestinal microorganisms (in a suspension of a

healthy donor stool) into the intestine of an infected patient (Gough, Shaikh, & Manges, 2011).
This allows for the restoration of a healthy microbiota, which theoretically will overpower the
colonizing C. difficile. In a systematic literature review study of IMT treatment for recurrent CDI,
IMT was shown to be highly effective in eradicating C. difficile, with resolution in 92% of
patients (Gough et al., 2011).
One hospital method that has been shown to be highly effective in reducing the
deterioration of patient’s microflora, and in turn C. difficile infections, is the implementation of
an antibiotic stewardship program (D. N. Gerding, Muto, & Owens, 2008). For example, the use
of high-risk antibiotics (second-generation cephalosporins, third-generation cephalosporins,
fluoroquinolones and clindamycin) has been positively correlated with a significant decrease in
the CDI incident rate by 0.0047/100 bed-days per month (Mamoon A. Aldeyab et al., 2012).
Further decreases were observed with implementing stewardship with medium-risk antibiotics
(amoxicillin/clavulanic acid and macrolides).
Our goal in this study is to determine if there was a causal relationship between the use
of hospital hand hygiene, the implementation of more sensitive PCR-based testing and the
promotion of an antibiotic stewardship program on the rate of hospital-associated C. difficile
infection (CDI).

METHODS
Study Design

A four-year retrospective study that compared the relationship between hospital hand
hygiene, CDI test sensitivity and an antibiotic stewardship program to hospital-associated CDI
rates was conducted from July, 2011 through September, 2015 at Southern Ohio Medical
Center (SOMC). CDI rates were gathered at monthly intervals.
Hospital
SOMC is a 222-bed not-for-profit hospital providing emergency and surgical care to the
residents of Ohio, with an average annual census of 13,000 patients admitted during the data
acquisition period.
C. Difficile Prevention Strategy
Three primary prevention strategies were implemented in this study:
The first is the hand hygiene policy implemented in 2011 to prevent hospital-associated
infections. In compliance with CDC, all employees were required to apply either soap and water
or alcohol-based hand gel immediately before entering and immediately upon exiting a
patient’s room using readily accessible hand hygiene stations. Hand hygiene compliance was
monitored and timely feedback was given to healthcare personnel if lapses in protocol were
observed. Although alcohol-based hand gels are efficient in the prevention of MRSA, they are
not efficient in eradicating C. difficile spores (Oughton, Loo, Dendukuri, Fenn, & Libman, 2009).
Therefore, mechanical removal with soap and water was used when treating patients with CDI.
To monitor hand hygiene compliance, random hospital-wide audits were conducted monthly on
all employees. Each time a healthcare employee (of any type) entered or exited a patient’s

room, the auditor recorded whether or not they applied soap and water and/or alcohol-based
hand gel.
The second strategy is antibiotic stewardship. In July of 2014, an antibiotic stewardship
team, which primarily focused to minimize the inappropriate use of broad spectrum antibiotics,
was implemented. Physician compliance to the program was of utmost importance.
The third is preventing the transmission of C. difficile spores. Three methods have been
implemented to curtail endospore transmission including: hand washing, isolation of positively
screen C. difficile patients, and the use of disinfectants on the environmental surfaces.
Asymptomatic patients with a history of C. Difficile are not put into isolation, but are screened
for C. difficile. For an asymptomatic patient to be put into isolation, they must have tested
positive for C. Difficile. Currently, this is an area of controversy, since some hospitals isolate
patients based on history alone. In addition, an EPA-registered, quaternary ammonium-based,
one step disinfectant with bactericidal properties, formulated to kill C. difficile spores, is used
by environmental services at the hospital.
C. Difficile Screening and Testing Methods
Our study used laboratory testing guidelines for C. difficile as outlined by The Society for
Healthcare Epidemiology of America (SHEA) and The Infectious Disease Society of America
(IDSA) (Cohen et al., 2010). Patients exhibiting three or more loose watery bowel movements
(diarrhea) within a 24 hour period are tested for C. difficile. However, as part of a nursing
protocol, asymptomatic patients with one loose bowel movement were often screened.

Two types of screening methods were used for identifying CDI; Toxin A and B Enzyme
Immunoassay (toxin A/B EIA), and Polymerase Chain Reaction assays (PCR assays). Toxin A/B
EIA test for the presence of C. difficile toxin A and toxin B in a patient’s stool sample. The run
time for a single toxin A/B EIA can take between thirty minutes to two hours and up to 24 hours
for a STAT C. difficile result. We consider the toxin A/B EIA too insensitive to be used as the
stand alone test to exclude CDIs. If a toxin A/B EIA yields a negative result, it is required to test
the specimen two to three more times, which may increase the time to confirm a negative
diagnosis to several days. For the average symptomatic patient, toxin A/B EIA screening is
conducted three times to increase the test’s sensitivity.
In January of 2013, SOMC adopted PCR-based testing as the main CDI diagnosing
method. PCR assays yield the highest sensitivity for detecting the presence of CDI through
amplified DNA testing of the C. difficile toxin genes. PCR assays are significantly more rapid,
taking approximately an hour to obtain a result with a 30% increase in sensitivity.
There are multiple testing algorithms that different hospitals and labs use for
determining the presence of C. difficile in a stool. However, these algorithms were not used.
PCR testing is only permitted on liquid stools and only one test every seven days, because a
single stool specimen can rule out the presence of C. difficile. It is possible to detect C. difficile
spores in the stool of patients who are just carrying C. difficile, and do not have a C. difficile
associated disease. Thus, only symptomatic patients were tested with this method. If a
specimen is not liquid, it is not tested, and thereby minimizes the risk of false positives. The
only exception to this is when ileus is suspected in an asymptomatic patient.

Specimens that test positive must also be interpreted in the context of the patient’s
history and presentation. Nearly everyone who has C. difficile associated disease has a history
of antibiotic usage in the past 3 months. This is important when deciding whether the onset of
diarrhea is caused by C. difficile. “Test of cure” C. difficile PCR was not conducted, because
lingering spores that would test as positive are possible even though the patient’s symptoms
may have resolved. The only “test of cure” necessary for C. difficile is the resolution of
symptoms.

RESULTS
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Figure 1: The rate of C. Difficile infections per month from July 2011 to September 2015 at SOMC. The number of
C. Difficile infection with hygiene protocol implementation in 2011, antibiotic stewardship program

implementation

in

July

2014,

and

PCR

screening

method

implementation

in

January

2013.

Our results do not support improving C. difficile infection rates by hospital hand hygiene
alone as the sole intervention. We found that since 2011, the overall CDI rate has increased
tenfold (0.073% to 0.702%). During this time period, very few instances of a decreasing trend
were observed. In addition, our data shows no reduction in C. difficile infection rates during
implementation of antibiotic stewardship. However, the compliance of staff and physicians to
both of the methods could be the cause for the lack of reduction in infection rates.
Our results do support a significant increase in sensitivity for C. difficile testing using PCR
assays (p < 0.05). This observation suggests that PCR-based testing for CDI diagnosis has a
higher sensitivity for detecting the presence of C. difficile toxins compared to other methods
and will result in a more accurate diagnosis of CDI.

DISCUSSION
Placing alcohol-based hand antiseptics in easily-accessible areas of all units in the
hospital is successful in improving hand hygiene compliance (John M. Boyce, 2000; Cookson et
al., 2001). Alcohol-based hand antiseptics placed conveniently at the point of care allows
healthcare employees to effectively reduce vegetative bacteria on their hands much faster.
However, C. difficile spores negate these beneficial effects of alcohol-based hand antiseptics
(Wullt, Odenholt, & Walder, 2003).

One could hypothesize that the absence of a relationship between CDI rates and
hospital hand hygiene in our study is due to the mistaken use of alcohol-based antiseptics
instead of mechanical hand washing. By eliminating competing bacteria in the facility’s
microbiome, it is theoretically possible that this even promoted CDI (J. M. Boyce, Ligi, Kohan,
Dumigan, & Havill, 2006; Horner, Mawer, & Wilcox, 2012; Jabbar et al., 2010; McFarland,
Mulligan, Kwok, & Stamm, 1989).
PCR assays vs. toxin A/B EIA. There has been much debate on whether PCR assays or
toxin A/B EIA are most effective in testing for C. difficile toxins. According to a recent study,
approximately 90% of laboratories in the United States prefer toxin A/B EIA opposed to PCR,
because they are easy to use and cost efficient (Johnson et al., 2001). However, toxin A/B EIA
has been shown to lead to low negative predictive values leading to false-positive results, due
to their low sensitivity (Gould & McDonald, 2009). As a result multiple tests are needed for a
positive confirmation, which lengthens the time frame for diagnosis.
Generally, the majority of C. difficile colonized in a person exists as spores (McFarland et
al., 1989). Since only one PCR assay needs to be run, eliminating a CDI diagnosis is much faster.
It is beneficial to diagnosis patients early with CDI, so that treatment can begin before the
spores germinate. However, the downside to this is the possibility of colonization causing a
false positive in an uninfected patient with loose bowel movements. This was prevented by
only permitting PCR assays to symptomatic patients. If the stool specimen is not liquid, it was
not tested.

The CDC has indicated that PCR is “too sensitive”, postulating that it detects colonization
within the organism, instead of the disease itself. An accompanying commentary stated that up
to 15% of hospitalized patients are colonized with C. difficile, but is the etiological agent of
diarrhea in only 5-10% of them. This suggests that the low positive predictive value of PCR
assays (44.7%) translates into false positives for infectious disease, and emphasizes the
importance of analyzing patient history with the test results.
After the antibiotic stewardship team’s implementation, the first decreasing trend in CDI
rates (-0.07% from January-June 2015) since PCR assays were in place was observed. Dancer, et
al., have observed that an antibiotic stewardship program restricting the use of ciprofloxacin
and ceftriaxone can reduce CDI by over 70% (Dancer et al., 2013). Our program restricted the
use of several antimicrobials; however, we did not see an overall trend in reduction.
The antimicrobial stewardship team placed a strong focus on thoroughly educating the
physicians and promoting their compliance. They provided a selection of lower risk
antimicrobials (for other infections) when possible, and encouraged avoiding antibiotics unless
an indicated condition was present. It was found that an effective antibiotic stewardship
initiative is essential to slowing the incidence of CDI.
Prior data suggests that 30-50% of all hospitalized patients receive some kind of
antimicrobial/antibiotic treatment (Metjian, Prasad, Kogon, Coffin, & Zaoutis, 2008). The use of
antibiotics in over 50% of cases in the United States was deemed unnecessary and/or
inappropriate (Fishman, 2006). Since most cases of CDI occur in patients previously exposed to
prolonged cycles of antibiotics, this poses a serious threat for CDI.

As part of the antibiotic stewardship program, a semi-annual antibiogram was put in
place to monitor the use of antibiotics. This provides statistics of what antibiotics are effective
against different organisms, and provides information on narrow spectrum drugs for those
organisms. It has been shown that increasing the duration of patient exposure to antimicrobials
increases the risk of resistant organisms colonizing (McGowan, 1983). The antibiogram assists in
preventing the overuse of broad-spectrum drugs, while preserving the effectiveness of the
antibiotics available. Over usage of antibiotics puts a selective pressure on microorganisms to
develop resistance, so by using the antibiogram a physician can select the appropriate antibiotic
to alleviate an infection.
The goal of an antibiotic/antimicrobial stewardship program is to treat all patients with
the appropriate antibiotic that is both cost effective and of least toxicity, while optimizing its
dosage, duration of treatment, and de-escalation in order to help prevent the spread of
infection (Fishman, 2006; Piacenti & Leuthner, 2013; Shlaes et al., 1997). It is crucial that we
control and monitor specific antibiotic usage throughout the hospital by integrating hospital
guidelines, staff education, and enforcement of infection control policies (Piacenti & Leuthner,
2013). In several hospitals that placed restrictions on antimicrobials, similar to our study, a
reduction in both the incidence and prevalence of resistant organisms was observed
(Bamberger & Dahl, 1992; Berk, Alvarez, Ortega, Verghese, & Holtsclaw-Berk, 1986; BETTS et
al., 1984; D. Gerding et al., 1991; King, White, Todd, & Conrad, 1992; McGowan, 1994; Pear,
Williamson, Bettin, Gerding, & Galgiani, 1994; Van Landuyt, Boelaert, Glibert, Gordts, &
Verbruggen, 1986; YOUNG, SEWELL, KOZA, & CLARRIDGE, 1985). In another study, the

incorporation of an antibiotic stewardship program was shown to significantly decrease the
rates of selected nosocomial infections (Frank et al., 1996).
Recently, C. difficile-associated diarrhea has posed major threat to patients prescribed
antibiotics, deeming it more a public health concern than antimicrobial resistance (Piacenti &
Leuthner, 2013). In a secondary/tertiary-care hospital in Quebec, an interrupted time-series
analysis studied the influence a nonrestrictive antibiotic stewardship program had on the
incidence of nosocomial C. difficile-associated disease during an epidemic. They found from
2003-2004 to 2005-2006, total and targeted antibiotic usage decreased by 23% and 54%,
respectively, and a 60% decrease in the incidence of nosocomial C. difficile associated disease
was observed (Valiquette, Cossette, Garant, Diab, & Pépin, 2007). In a similar study that
evaluated the impact of antibiotic stewardship focused on high-risk antibiotics, they found a
borderline significant reduction in high-risk antibiotic usage associated with a significant
reduction in the CDI rate by 0.0047/100 bed days per month (M. A. Aldeyab et al., 2012). In
several other published studies, antibiotic stewardship programs have demonstrated to be
highly successful in the improvement of patient outcomes, reducing CDIs in hospital settings,
and reducing readmission rates (Bishop, Parry, & Hall, 2013; Dortch et al., 2011; Fridkin &
Srinivasan, 2013; Goff et al., 2012; Malani et al., 2013; Pasquale et al., 2014; Yong, Buising,
Cheng, & Thursky, 2010).
All things considered, when faced with the current crisis of the emerging incidences of
CDIs and C. difficile associated diseases amongst hospitals, our data shows no improvement in
infection rates with hand hygiene and antibiotic stewardship programs. Despite these odds,

infectious disease specialists still highly recommended that hospitals incorporate similar
prevention strategies based off of the results of other studies (Goldstein et al., 2015). However,
our results do suggest PCR assays should be used to screen and diagnose C. difficile infections in
patients. Utilizing PCR screening methods which provide quick and accurate results may help
prevent the spread of C. difficile between patients.
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